Mayne Pharma Group Gestione

Gestione criteri di controllo 1/4

Mayne Pharma Group Il CEO è Shawn O’Brien, nominato in Oct2022, e ha un mandato di 2.08 anni. la retribuzione annua totale è A$ 2.06M, composta da 46.5% di stipendio e 53.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.075% delle azioni della società, per un valore di A$ 254.40K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 2.7 anni.

Informazioni chiave

Shawn O’Brien

Amministratore delegato

AU$2.1m

Compenso totale

Percentuale dello stipendio del CEO	46.5%
Mandato del CEO	2.1yrs
Proprietà del CEO	0.07%
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	2.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Sep 01

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Shawn O’Brien rispetto agli utili di Mayne Pharma Group?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	AU$2m	AU$959k	-AU$169m
Mar 31 2024	n/a	n/a	-AU$221m
Dec 31 2023	n/a	n/a	-AU$274m
Sep 30 2023	n/a	n/a	-AU$296m
Jun 30 2023	AU$2m	AU$663k	-AU$317m

Compensazione vs Mercato: La retribuzione totale di Shawn ($USD 1.34M ) è superiore alla media delle aziende di dimensioni simili nel mercato Australian ($USD 708.27K ).

Compensazione vs guadagni: La retribuzione di Shawn è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Shawn O’Brien (65 yo)

2.1yrs

Mandato

AU$2,062,194

Compensazione

Mr. Shawn Patrick O'Brien, B.Sc has been CEO, MD & Director at Mayne Pharma Group Limited since October 1, 2022. He serves as the Chief Commercial Advisor at Melanovus Oncology, Inc. Mr. O'Brien is a found...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Shawn O’Brien	CEO, MD & Director	2.1yrs	AU$2.06m	0.075% A$ 254.4k
Aaron Gray	Chief Financial Officer	2.3yrs	AU$1.31m	0.064% A$ 216.0k
Kimberly Parker	Executive VP & General Counsel	2.8yrs	Nessun dato	Nessun dato
Brant Schofield	Executive Vice President of Corporate Development	3.8yrs	AU$1.29m	Nessun dato
Erinn Nathaniel	Director of Global Human Resources	1.8yrs	Nessun dato	Nessun dato
Daniel Moore	Executive Vice President of Commercial	5.2yrs	Nessun dato	Nessun dato
Frank Casty	Executive VP & Global Chief Medical Officer	1.8yrs	Nessun dato	Nessun dato
Brenton Walter	Financial Controller	20.3yrs	Nessun dato	Nessun dato
Laura Loftus	Associate General Counsel & Company Secretary	4.7yrs	Nessun dato	Nessun dato

2.8yrs

Durata media

Gestione esperta: Il team dirigenziale di MYX è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Shawn O’Brien	CEO, MD & Director	2.1yrs	AU$2.06m	0.075% A$ 254.4k
Frank Condella	Independent Non-Executive Chairman	6.5yrs	AU$305.40k	0.081% A$ 275.6k
Bruce Robinson	Independent Non-Executive Director	10.3yrs	AU$219.39k	0.039% A$ 132.7k
Patrick Blake	Independent Non-Executive Director	6.4yrs	AU$218.36k	0.027% A$ 92.4k
Ann Custin	Independent Non-Executive Director	2.7yrs	AU$235.16k	0.026% A$ 89.3k
Kathryn MacFarlane	Independent Non-Executive Director	2.8yrs	AU$215.84k	0.047% A$ 158.8k
Anne Lockwood	Independent Non Executive Director	less than a year	AU$117.49k	Nessun dato
David Petrie	Non-Executive Director	2.2yrs	AU$217.86k	Nessun dato

2.7yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di MYX non è considerato esperto (durata media del mandato 2.7 anni), il che suggerisce un nuovo consiglio.

Mayne Pharma Group Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Recent updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Price target decreased by 12% to AU$6.09

New major risk - Financial position

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

New minor risk - Profitability

Consensus revenue estimates increase by 14%, EPS downgraded

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Consensus estimates of losses per share improve by 13%

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Consensus estimates of losses per share improve by 13%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Consensus revenue estimates fall by 19%

Price target decreased by 24% to AU$3.86

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Consensus revenue estimates fall by 11%

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Consensus forecasts updated

Price target decreased to AU$0.37

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Price target decreased to AU$0.40

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

Price target increased to AU$0.43

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Price target decreased to AU$0.36

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 97%

Mayne Pharma Expands U.S Dermatology Portfolio

Price target increased to AU$0.48

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Independent Non-Executive Director recently bought AU$137k worth of stock

Price target decreased to AU$0.42

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published